26623-16-5Relevant articles and documents
COMPOUNDS FOR THE TREATMENT OF SYSTEMIC INSULIN RESISTANCE DISORDERS AND THE USE THEREOF
-
Paragraph 00260-00262, (2018/12/03)
Aspects of the invention relate to novel synthetic compounds for treatment of metabolic diseases partially associated with systemic insulin resistance caused by Galectin proteins binding and inhibiting insulin and TGFb1 receptors causing physiological disturbances in the insulin pathways.
Synthesis of 1,2,3-triazole glycoconjugates as inhibitors of α-glucosidases
Da Rocha, David R.,Santos, Wilson C.,Lima, Emerson S.,Ferreira, Vitor F.
experimental part, p. 14 - 19 (2012/03/26)
Ten new 1,2,3-triazole glycoconjugates were synthesized from d-glucose and evaluated in in vitro assays for their ability to inhibit the enzyme α-glucosidase. Most of the compounds had low activity or were inactive when compared with acarbose. However, the derivative 1,2-O-isopropylidene-3- phenyl-5-(4-phenyl-1H-1,2,3-triazole-1-yl)-α-d-ribofuranose (19i) possessed activity comparable with the standard drug. The influence of the phenyl group on carbon 3 of the carbohydrate framework is discussed.
Biologically potent L-hexoses and 6-deoxy-L-hexoses: Their syntheses and applications
Kulkarni, Suvarn S.,Chi, Fa-Chen,Hung, Shang-Cheng
, p. 1193 - 1200 (2007/10/03)
This account describes our recent work in the development of new methodologies to prepare rare and biologically potent L-hexoses and 6-deoxy-L-hexoses, from cheapest D-glucose, via L-hexofuranoses and 1,6-anhydro-β-L-hexopyranoses as key building blocks. Their applications in the syntheses of heparin oligosaccharides, the carbohydrate moiety of bleomycin A2, and L-acovenose are also summarized here.